The last decade has seen the development and refinement of predictive risk stratification models in the management of prostate cancer (CaP) ([@bib22]). These tools are validated for clinical decision-making and facilitating informed patient consent to treatment.

These tools aim to apply an objective, evidence-based algorithm to a set of disease parameters, thus moving away from subjective judgments based on clinical experience. Unsurprisingly given the genetic and molecular heterogeneity between individuals, these tools are far from perfect. They cannot always determine an individual\'s likelihood of clinically significant disease, particularly in classically low to intermediate risk groups, and in those patients undergoing active surveillance (AS) ([@bib28]; [@bib16]). Increased understanding of the molecular biology of CaP has identified some biomarkers that are predictive of disease outcome and therapeutic response to treatment ([@bib2]), for complementary use with the serum PSA test and histological Gleason score assessment.

The TransAtlantic Prostate Cancer Group developed a 31 gene cell-cycle progression (CCP) signature for predicting outcome in CaP ([@bib8], [@bib7]) using conservatively treated transurethral resected prostate (TURP) samples, and validated CCP in radical prostatectomy and initial needle core biopsy ([@bib7]). Another predictive test is the commercially available multigene RT--PCR Oncotype DX Prostate Cancer Assay (Genomic Health, Redwood City, CA, USA). A 17-gene panel assesses markers of 4 distinct biological targets: the androgen pathway (AZGP1, KLK2, SRD5A2 and FAM13C), cellular organisation (FLNC, GSN, TPM2 and GSTM2), proliferation (TPX2) and stromal response (BGN, COL1A1 and SFRP4), to produce a 'genomic prostate score\' that predicts the likelihood of high-grade/stage disease at diagnosis ([@bib13]; [@bib12]).

Cancer cell proliferation is a surrogate of tumour growth and is associated with worsened prognosis in CaP and other cancer types ([@bib25]; [@bib21]). Unsurprisingly, measuring the proportion of cancer cells undergoing cell proliferation using the immunohistochemical proliferation marker Ki67 has shown promise as a biomarker for predicting biochemical recurrence in patients with localised CaP ([@bib3]). In addition, Ki67 has been reported to predict distant metastasis formation in intermediate CaP, following radiation therapy ([@bib27]) and in conjunction with other markers post docetaxel chemotherapy ([@bib1]). It has also demonstrated predictive value in assessing overall survival (OS) and disease-specific survival (DSS) ([@bib10]). However, there is a lack of consensus when assigning thresholds for dichotomously categorising patients, which have varied from 2.4 to 26% for biochemical recurrence and from 3 to 10.3% for DSS.

There remains an unmet need to identify markers capable of reliably assessing an individuals\' risk of developing metastasis and castrate resistance. These are important end points for clinical assessment because they are associated with worsening prognosis. In this study, we attempt to validate recent work carried out by [@bib10] in which they used a single biomarker, Ki67, to predict outcome in a conservatively managed group of patients diagnosed on needle core biopsy. They demonstrated that Ki67 has significant ability to predict CaP-specific death on both univariate and multivariate analysis (compared with PSA and Gleason score). Ki67 has previously been demonstrated to predict survival and recurrence in patients undergoing radical treatment ([@bib23]; [@bib11]; [@bib31]). However, Fisher\'s work was the first study to demonstrate its prognostic utility from diagnostic biopsy in conservatively managed patients. This is important as this prognostic information could be used as an adjunct in clinical decision-making to reduce the number of patients requiring radical treatment, with all its attendant risks.

However, Fisher\'s group did not report whether Ki67 is predictive of metastasis. We therefore decided to examine the relationship between Ki67 expression and subsequent metastases and also applied a bioinformatic learning tool, artificial neural network (ANN) analysis, to identify further biomarkers of metastasis development and DSS in a contemporary gene array library of an unselected population of CaP patients.

Materials and Methods
=====================

Patient selection and clinical data collection
----------------------------------------------

About 365 Patients diagnosed with CaP between 1999 and 2001 were identified. These were consecutive non-selected patients and all underwent 'best-practice\' treatment at Nottingham City Hospital, UK. Initial histological cancer diagnosis was made using tissue obtained by prostate needle core biopsy or TURP specimens. A total of 192 patients were selected for inclusion in the study; 155 patients were excluded to improve cohort homogeneity. Exclusion criteria included patients not undergoing TURP (29), patients lost to follow-up or key parameters not recorded (114). Gleason scoring was modified in 2005 by the International Society of Urological Pathology (ISUP) consensus ([@bib9]), and for this reason all cases were histologically reviewed and Gleason scored using contemporary ISUP guidelines. Multiple clinicopathological variables were recorded for each patient including PSA and histological Gleason score at diagnosis, time taken to metastasis formation and time taken to CaP-specific death post-diagnosis. Patient management was based on PSA levels, histology Gleason score and clinical staging. Patients were clinically followed-up at 3--6 monthly intervals and the majority of patients received 'watchful waiting\'. Androgen deprivation therapy was given for disease progression, indicated by a rapid rise in PSA level, symptoms or metastasis development. Palliative radiotherapy or chemotherapy was administered for symptom control (bone pain or prostate bleeding) in patients with late-stage cancer.

Use of the tissue samples for this study was approved by the North West 7 Research Ethics Committee--Greater Manchester Central REC number 10/H1008/72.

TMA construction
----------------

A tissue microarray (TMA) was constructed using archival wax-embedded TURP tissue samples sourced via the Nottingham Health Science BioBank. Histology sections were reviewed by a pathologist (GH) and 0.6 mm diameter donor cores were sampled from at least two different tumour regions per patient using an automated TMA Grand Master instrument (3DHistech, Budapest, Hungary).

Biomarker selection
-------------------

Artificial neural network techniques were applied to a publically available CaP cDNA gene expression array ([@bib29]) to identify biomarkers for predicting tumour metastasis ([@bib24]) so that their performance could be compared with the proliferation marker Ki67. We have previously reported on the use of an ANN technique to identify predictors of metastasis ([@bib24]). Here the ANN model was reiterated 50 times with random sampling and the average mean square error of a test subset for each input variable was considered to determine the predictive capability for metastasis class.

The top 10 genes ranked for association with metastasis development are included in [Table 1](#tbl1){ref-type="table"}. Four of these had commercially available antibodies (AMACR (Racemase), DLX2, PAICS and MYO6). DLX2 was selected for validation due to its novelty as a candidate marker in CaP, its putative oncogenic function ([@bib5]; [@bib20]) and its high ANN ranking. For comparison, a curated literature search was performed to identify evidence for the application of Ki67 as a marker of outcome in CaP ([@bib3]; [@bib1]; [@bib10]; [@bib27]).

Immunohistochemistry
--------------------

Optimal antibody dilutions and antigen retrieval conditions were performed using positive and negative control tissues suggested by the antibody suppliers. After microwave antigen retrieval in 10 m[M]{.smallcaps} sodium citrate, slides were sequentially incubated in the primary antibody, detection reagents (Leica Microsystems (UK) Ltd., Milton Keynes, UK) and haematoxylin.

Immunostained TMA sections were assessed to determine the appropriate scoring technique for quantifying protein expression levels. Sections were independently scored (WJFG, DGP) without knowledge of pathology grade. Ki67 and DLX2 nuclear staining was microscopically assessed at × 20 in tumour cells present in the TMA core, using a Histochemical score technique (H-score ([@bib18])). The H-score is achieved by summing the product of percentage cells showing each level of staining intensity where 0=absence of staining, 1=weak staining, 2=moderate staining and 3=strong staining intensity. Staining thresholds used for dichotomous categorisation were chosen using the software program X-tile ([@bib4]), or by those given in previously published studies. Patients were dichotomously categorised according to the nuclear H-score: positive expression was defined as a score ⩾110 for Ki67 and ⩾10 for DLX2.

We used REMARK guidelines ([@bib19]) for reporting on prognostic biomarkers in the whole patient series. The proportion of patients with scorable tissue sections was less than the total number of patients originally incorporated in the TMA due to detachment of cores during processing and because not every section taken from every core contained cancer tissue (independently reviewed by GH). Missing data was assessed for randomness using Little\'s test ([@bib15]) and Wilcoxon--Mann--Whitney test, both at 95% confidence level. We failed to reject the null hypothesis of data being missing completely at random (*P*\>0.05). The proportion of patients with tissue sections suitable for scoring is shown in [Table 2](#tbl2){ref-type="table"}.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS (Version 21; IBM, Portsmouth, Hampshire, UK) applied to verified cancer samples. Pearson\'s *χ*^2^-tests were performed to assess biomarker associations with clinicopathological variables including initial PSA and Gleason score. Kaplan--Meier plots with log-rank tests were used to model biomarker associations with DSS (months) and time (months) to metastasis development from diagnosis. Biomarkers also underwent multivariate Cox proportional hazards regression modelling to assess the additional prognostic value to the initial PSA at diagnosis, Gleason score and initial D\'Amico risk category. The significance level used was *P*\<0.05. If during biomarker analysis a particular clinicopathological variable was missing (e.g., if it had never been recorded in the notes) then that patient would be excluded from the statistical calculation.

Results
=======

Patient characteristics are shown in [Table 3](#tbl3){ref-type="table"}. Examples of nuclear Ki67 and DLX2 staining are shown in [Figure 1](#fig1){ref-type="fig"}.

Ki67
----

A total 161 out of 192 (83.9%) patients samples had scorable tissue with 11 (6.8%) and 150 (93.2%) showing positive and negative staining, respectively. Increased nuclear Ki67 expression showed a negative association with OS (*χ*^2^=9.493, *P*=0.002) and DSS (*χ*^2^=5.222, *P*=0.022; [Figure 2A](#fig2){ref-type="fig"}) and a positive association with metastatic disease (*χ*^2^=5.058, *P*=0.025; [Figure 2B](#fig2){ref-type="fig"}). Subsequent multivariate Cox regression analysis demonstrated that Ki67 contributed additional predictive ability to PSA concentration, Gleason score and initial D\'Amico risk for DSS (HR=2.436, *P*=0.029, 95% CI=1.096--5.416) and metastasis risk (HR=3.296, *P*=0.023, 95% CI=1.1814--9.196) ([Table 4](#tbl4){ref-type="table"}). All Ki67-positive patients had high-grade cancer (Gleason score 8--10, Groups 4--5), and in addition 8 out of 11 (72.7%) Ki67-positive patients showed co-expression with DLX2.

DLX2
----

A total 185 out of 192 patients samples had scorable tissue with 135 (73%) and 50 (27%) showing positive and negative staining, respectively. DLX2 expression was not associated with Gleason score or PSA levels. DLX2 alone was not found to be predictive of DSS (*χ*^2^=2.282, *P*=0.131) ([Figure 2C](#fig2){ref-type="fig"}) but increased nuclear DLX2 expression showed a positive association with metastasis development (*χ*^2^=10.207, *P*=0.001; [Figure 2D](#fig2){ref-type="fig"}), independent of PSA concentration, Gleason score and initial D\'Amico risk using multivariate Cox regression analysis (HR=2.754, *P*=0.003, 95% CI=1.423--5.332) ([Table 4](#tbl4){ref-type="table"}). Co-expression with high Ki67 staining was seen in 8.2% DLX2-positive tumours.

Discussion
==========

This study compares the utility of two biomarkers to predict CaP survival and risk of metastasis in an unselected cohort of CaP patients with at least 10 years of clinical follow-up. Biomarker selection was based on recent studies highlighting Ki67 as a marker of cell proliferation and outcome in CaP ([@bib23]; [@bib3]; [@bib11]; [@bib31]; [@bib1]; [@bib27]) and a bioinformatic ANN approach applied to a gene expression array derived from CaP patients, interrogated for markers of metastases. Development of metastasis was associated with increased expression of the tumour markers Ki67 and DLX2. To the best of our knowledge this is the first study of DLX2 being used as a marker of disease progression in CaP. Interestingly, co-expression of Ki67 and DLX2 occurred in 6.8% (11 out of 161) scorable patients and was characterised by high cancer grade (Gleason 8--10) and high risk of metastasis.

Ki67 is functionally associated with cellular proliferation and is a surrogate for the growth fraction of tumours. It has been reported to be predictive of CaP-specific mortality ([@bib31]; [@bib1]; [@bib27]) and we confirm that Ki67 provides prognostic information on disease-specific and OS in CaP. Furthermore, we demonstrated that Ki67 provides additional prognostic utility (HR: 2.19) to the PSA and Gleason score, validating the study by [@bib10] who recently reported that Ki67 from biopsy tissue independently predicts survival in CaP (HR: 2.78).

In addition to validating Fisher\'s work ([@bib10]), we also demonstrated that Ki67 expression is predictive of future metastases in CaP, adding to the small but growing cohort of potential markers of metastasis in this disease. For example, recent work by [@bib6] has examined the expression of three putative stem cell markers (integrin alpha 2 and 6 and CMET) in men with high-risk CaP. They concluded that the proportion of stem cell-like cancer cells is predictive of bone metastases.

Interestingly only 6.8% (11 patients) of our cancer cohort had a significantly raised Ki67 and we propose that such patients could be counselled regarding an increased risk of death and metastasis, particularly if they are also positive for DLX2, and should be considered for an AS programme. Both markers are known to be functionally important in cancer cell proliferation and, coupled with their association with high Gleason grade reported here, these findings fit with a hypothesis that tumour proliferation rates are a surrogate for tumour aggression and poor prognosis.

Using an ANN approach DLX2 was identified as a marker for metastasis prediction. DLX gene family is involved in embryonic development, tissue homoeostasis, cell cycle and apoptosis ([@bib26]). A growing number of homeobox genes have been shown to be deregulated in a variety of human tumours, and their deregulation is known to enhance cell survival and proliferation and prevent differentiation ([@bib14]). Aberration is reported in breast, lung, ovarian and colon tumours ([@bib20]), and early work has shown that these genes may be involved in neuroendocrine differentiation seen in advanced CaPs ([@bib5]) but no association with clinical outcomes has ever been reported.

DLX2 has been reported to be involved in shifting TGF*β* from a tumour suppressor to a tumour-promoting function by repressing TGF*β*RII and the cell-cycle inhibitor p21CIP1, and simultaneously increasing the mitogenic transcription factors c-Myc and epidermal growth factor ([@bib30]). In addition, it has been suggested that DLX2 activity may suppress TGF-*β*-mediated cell adhesion and migration inhibition ([@bib17]). Our novel DLX2 findings validate the ANN bioinformatics approach in revealing it to be a strong predictor of increased metastasis risk (HR: 3.311), more so than either the PSA or Gleason score. DLX2 therefore warrants further investigation because of its ability to assess cancer cell-survival potential.

In summary, we demonstrate that two cell proliferation markers, Ki67 and DLX2, appear to predict CaP-specific survival and metastasis. Independent validation of these findings is needed to establish if Ki67 and DLX2 (especially co-expression) should be considered for prospective clinical trials.
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![**Ki67 and DLX2 localisation in prostate cancer.**Examples of positive Ki67 (**A**) and DLX2 (**B**) nuclear prostate cancer staining compared with tumours that did not express Ki67 (**C**) or DLX2 (**D**).](bjc2016169f1){#fig1}

![**Ki67 and DLX2 are predictive biomarkers of disease progression risk in prostate cancer.**Kaplan--Meier plots demonstrating (**A**) prostate-specific cancer death over time according to Ki67 score. (**B**) metastasis development over time according to Ki67 score. (**C**) prostate-specific cancer death over time according to DLX2 score. (**D**) metastasis development over time according to DLX2 score.](bjc2016169f2){#fig2}

###### ANN ranked gene list showing association with prostate cancer metastasis

  **Rank**   **Gene accession number**   **Gene name**   **Gene product (protein)**
  ---------- --------------------------- --------------- -------------------------------------------------------------------------------------------
  1          AK022765.1                  *AMACR*         Alpha-methylacyl-CoA racemase
  2          AI796120                    *AMACR*         Alpha-methylacyl-CoA racemase
  3          AF047020.1                  *AMACR*         Alpha-methylacyl-CoA racemase
  4          NM_004405.2                 *DLX2*          Distal-less homeobox 2
  5                                      *PCA3*          Prostate cancer antigen 3
  6          NM_012485.1                 *HMMR*          Hyaluronan-mediated motility receptor (RHAMM or CD168)
  7          U90236.2                    *MYO6*          Myosin VI
  8          NM_017636.1                 *FLJ20041*      Hypothetical protein FLJ20041 Alias: TRPM4B
  9          BF511718                    *RHO7*          GTP-binding protein Rho7 Alias: RND2
  10         NM_006452.1                 *ADE2H1*        Multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase Alias: PAICS
  11         NM_002570.1                 *PACE4*         Paired basic amino acid cleaving system
  12         NM_004503.1                 *HOXC6*         Homeobox C6

###### The number of patients within the prostate cancer cohort that were dichotomously categorised for each biomarker

  **Biomarker (score)**    **Number of cancer patients scored**   **Number positive (%)**   **Number negative (%)**
  ----------------------- -------------------------------------- ------------------------- -------------------------
  Ki67 (\>110)                             161                           11 (6.8)                 150 (93.2)
  DLX2 (\>10)                              185                           135 (73)                   50 (27)

###### Characteristics of prostate cancer patients incorporated in the TMA

  **Clinical variable**                       **Number of patients (%)**   **Chemotherapy**   **Androgen depletion therapy including orchidectomy (% All patients)**  **Radiotherapy (% All patients)**
  ------------------------------------------ ---------------------------- ------------------ ------------------------------------------------------------------------ -----------------------------------
  **PSA (ng ml**^**−1**^**) at diagnosis**                                                                                                                            
  ⩽4                                                   18 (9.4)                                                                                                        
  \>4                                                 168 (87.5)                                                                                                       
  Not recorded                                        6 (3.125)                                                                                                        
  **Gleason score**                                                                                                                                                   
  Group 1: ⩽6                                          7 (3.6)                 1 (0.52)                                      6 (3.1)                                  0
  Group 2: 3+4                                        22 (11.5)                5 (2.6)                                        4 (2)                                   0
  Group 3: 4+3                                        31 (16.1)                5 (2.6)                                       6 (3.1)                                  2 (1)
  Group 4: 8                                          42 (21.9)                9 (4.7)                                       8 (4.1)                                  0
  Group 5: 9--10                                      90 (46.9)               43 (22.4)                                     30 (15.6)                                 3 (1.5)
  **Metastasis**                                                                                                                                                      
  At diagnosis                                        32 (16.6)                                                                                                        
  Subsequent metastasis                                73 (38)                                                                                                         
  Never developed metastasis                          87 (45.3)                                                                                                        
  **Death due to prostate cancer**                                                                                                                                    
  Yes                                                 105 (54.7)                                                                                                       
  No                                                  55 (28.6)                                                                                                        
  Still alive                                         20 (10.4)                                                                                                        
  Not recorded                                         12 (6.2)                                                                                                        

Abbreviation: TMA=tissue microarray.

###### Multivariate analysis was performed to assess the predictiveness of Ki67 and DLX2 compared with PSA concentration, Gleason groups and D\'Amico risk

                                                    **95% Confidence interval**  
  -------------------------------- ------- ------- ----------------------------- -------
  **Ki67 survival prediction**                                                   
  Ki67                              0.029   2.436              1.096              5.416
  PSA concentration                 0.290   1.00               1.000              1.000
  Gleason categories                0.936   1.018              0.659              1.572
  D\'Amico risk                     0.964   0.919              0.347              2.433
  **Ki67 metastasis prediction**                                                 
  Ki67                              0.023   3.296              1.181              9.196
  PSA concentration                 0.131   1.001              1.000              1.002
  Gleason categories                0.146   1.469              0.874              2.469
  D\'Amico risk                     0.325   0.600              0.217              1.660
  **DLX2 metastasis prediction**                                                 
  DLX2                              0.003   3.051              1.451              6.418
  PSA concentration                 0.202   1.002              0.999              1.004
  Gleason categories                0.768   1.081              0.643              1.819
  D\'Amico risk                     0.827   0.891              0.316              2.511

Abbreviation: PSA=prostate specific antigen.
